Top Medical News
10 hours ago
Patients aged ≥70 years are less likely to have hepatocellular carcinoma (HCC) within Milan criteria at diagnosis, less likely to receive any HCC treatment and have significantly lower long-term survival, according to a study of US adults.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. James Yang, Yesterday
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
Dr. Joseph Delano Fule Robles, Yesterday

Investigators from the Chinese University of Hong Kong (CUHK), the University of Toronto, Canada and Utrecht University, The Netherlands, recently showed that consumption of high-energy food after 10 PM was significantly associated with breast cancer. 

Christina Lau, Yesterday

In patients with non-small-cell lung cancer (NSCLC), mutations conferring treatment resistance are variable between biopsies, a study presented at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco, California, US has shown.

Audrey Abella, 2 days ago
Pregnancy simultaneously occurring with breast cancer does not adversely affect survival, according to a new study.
3 days ago
Hypertension is associated with an increased risk of breast cancer, particularly among postmenopausal women, a new meta-analysis finds.
4 days ago
Widely reported to be protective against several types of cancers, the Mediterranean diet (MD) does not appear to have any effect on the risk of pancreatic cancer as reported in the EPIC* study.
Special Reports
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. James Yang, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
Jairia Dela Cruz, 06 Dec 2016
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
Pearl Toh, 29 Nov 2016
New-generation therapies targeted toward specific genetic alterations such as EGFR and ALK mutations in non-small cell lung cancer (NSCLC) can overcome resistance to first-generation therapies and improve survival of patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
Conference Reports
Dr. Angela V. Ignacio, 20 Mar 2017
Among breast cancer survivors, engaging in high levels of physical activity before or around the time of diagnosis may decrease the risk of developing cardiovascular events (CVE) and dying from coronary heart disease (CHD) after receiving cancer therapy, according to a study presented at the American College of Cardiology’s 66th Annual Scientific Session in Washington, DC.
09 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

28 Feb 2017
Slideshow: Highlights from the 7th Association of South-East Asian Pain Societies (ASEAPS) Congress 2017
Tristan Manalac, 25 Feb 2017
Compared with viral hepatocellular carcinomas and those of other aetiologies, cryptogenic hepatocellular carcinomas tend to manifest at later stages and are associated with worse survival, according to a study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2017).
24 Feb 2017
Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, February 15 - 19.
Jackey Suen, 24 Feb 2017

Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.

Roshini Claire Anthony, 22 Feb 2017

Individuals with hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) have improved liver stiffness and a lower risk of hepatocellular carcinoma (HCC), according to a presentation at the Asian Pacific Association for the Study of the Liver annual meeting (APASL 2017) in Shanghai, China.

Product Highlights
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD